FDA names Dr. Vinay Prasad as top vaccine official
Show Caption
Hide Caption
Drugmaker shares sink after key FDA official ousted
Shares of U.S. drugmakers fell after reports that the Food and Drug Administration's top vaccine official had been forced to resign. The ouster of Dr. Peter Marks played a key role in developing COVID-19 vaccines during President Trump's first term.
The U.S. Food and Drug Administration has tapped Dr. Vinay Prasad, an oncologist who has previously criticized FDA leadership and COVID-19 mandates, as the director of its Center for Biologics Evaluation and Research (CBER), the agency said on May 6.
A harsh critic of the government's vaccine policies during the COVID-19 pandemic, Prasad will oversee the regulation of costly drugs, including vaccines, gene therapies and blood supply. He replaces Dr. Peter Marks, who led the division for 13 years and helped shape Operation Warp Speed to deliver vaccines during the pandemic.
The FDA's commissioner, Marty Makary, announced Prasad's appointment in an email to staff and on social media.
"Dr. Prasad brings the kind of scientific rigor, independence, and transparency we need at CBER — a significant step forward," Makary said.
A long-time COVID vaccine critic
In a recent blog post on the Substack platform, Prasad said the Centers for Disease Control and Prevention "should ABSOLUTELY remove COVID-19 from the Childhood Immunization schedule. If it stays, it shows the United States is a corrupt country," citing the lack of randomized trial evidence for use of the vaccines in children.
'The only 'emergency' America still faces with COVID-19 is that regulators like Peter Marks are either incompetent or corrupt to authorize a booster without clinical, randomized data,' he said.
Moreover, Prasad has been a harsh critic of his predecessor, Marks, calling him a 'mediocre academic' and "one of the most dangerous, pro-pharma regulators of the 21st century,' shortly after Marks resigned earlier this year.
Prasad comes to the FDA from the University of California, San Francisco, according to Reuters. He holds a medical degree from the University of Chicago, and has had stints at the National Cancer Institute and the National Institutes of Health.
Reuters contributed to the reporting on this story.
Fernando Cervantes Jr. is a trending news reporter for USA TODAY. Reach him at fernando.cervantes@gannett.com and follow him on X @fern_cerv_.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
an hour ago
- Bloomberg
Sarepta Needs to Show FDA Elevidys Won't Cause More Deaths
The Food and Drug Administration won't sign off on Sarepta Therapeutics Inc. bringing its controversial gene therapy back to the market until the company can persuade US regulators that it won't cause more deaths, according to an official familiar with the situation. The FDA has not seen a convincing explanation as to why Sarepta's gene therapy for Duchenne muscular dystrophy, Elevidys, was tied to two fatal cases of liver failure, the official said, and there may be no single, easily addressable problem the company can quickly fix. A third fatal case of liver failure that occurred during a trial of a separate but similar Sarepta gene therapy is unquestionably relevant information to the safety of Elevidys, said the official, who declined to be identified because the agency's deliberations are private.
Chicago Tribune
an hour ago
- Chicago Tribune
Oak Lawn bans kratom and THC products, though won't enforce for now
Despite the Oak Lawn Village Board voting Tuesday to prohibit the sale of kratom and THC products, Mayor Terry Vorderer says the village will wait to enforce the law. The prohibition of kratom and THC products, including Delta-9, was added to the tobacco retail regulation ordinance. But Vorderer said he learned from attorneys after the vote the ordinance may need to be reworked. 'They explained that that product is not really a tobacco product,' Vorderer said Wednesday. 'Thus, I instructed our staff not to enforce the kratom part, and we'll go back and modify or look at that.' The board tabled the measure after a June 24 meeting attendee attested to the benefits of kratom, saying he would do more research on the product. Kratom is an herbal substance from Southeast Asia commonly used for pain relief, mood enhancement and withdrawal symptoms. Though it is not regulated by the United State Food and Drug Administration, the FDA estimates about 2 million Americans used kratom in 2021. The ordinance amendment passed Tuesday stated the village was experiencing 'a proliferation of retail stores selling products containing potentially intoxicating ingredients,' including kratom and THC. 'These unregulated products result in certain adverse effects, including hallucination, vomiting, tremors, anxiety, dizziness, confusion and loss of consciousness, as well as negative impacts on certain brain functions related to memory, learning, decision making and emotions,' the ordinance states. Nearby communities have similarly worked to ban the sale of kratom and other drug products. In Tinley Park, the sale, distribution and use of kratom were made illegal last year, though businesses primarily profiting from kratom sales were given a 12-month amnesty period. The Orland Park Village Board passed a similar ordinance last May, banning kratom, tianeptine, Delta-8, and other novel synthetic and psychoactive drug products. Vorderer said he has worked to regulate the sales of drug products in Oak Lawn, saying 'we don't want to be in the drug dispensing business.' He said the Village Board previously voted not to allow marijuana dispensaries and capped the number of tobacco retailers at 12. Vorderer acknowledged he still has a lot to learn about products like kratom and their purported medical benefits and continues to discuss the affects of regulation with business owners. While for now the ban will not be enforced, village staff members will advise businesses if that changes, he said.
Engadget
an hour ago
- Engadget
FDA employees say the agency's Elsa generative AI hallucinates entire studies
Current and former members of the FDA told CNN about issues with the Elsa generative AI tool unveiled by the federal agency last month. Three employees said that in practice, Elsa has hallucinated nonexistent studies or misrepresented real research. "Anything that you don't have time to double-check is unreliable," one source told the publication. "It hallucinates confidently." Which isn't exactly ideal for a tool that's supposed to be speeding up the clinical review process and aiding with making efficient, informed decisions to benefit patients. Leadership at the FDA appeared unfazed by the potential problems posed by Elsa. "I have not heard those specific concerns," FDA Commissioner Marty Makary told CNN . He also emphasized that using Elsa and participating in the training to use it are currently voluntary at the agency. The CNN investigation highlighting these flaws with the FDA's artificial intelligence arrived on the same day as the White House introduced an " AI Action Plan ." The program presented AI development as a technological arms race that the US should win at all costs, and it laid out plans to remove "red tape and onerous regulation" in the sector. It also demanded that AI be free of "ideological bias," or in other words, only following the biases of the current administration by removing mentions of climate change, misinformation, and diversity, equity and inclusion efforts. Considering each of those three topics has a documented impact on public health, the ability of tools like Elsa to provide genuine benefits to both the FDA and to US patients looks increasingly doubtful.
